Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end

Dow Jones2021-09-14

MW Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end

Merck & Co. Inc. $(MRK)$ said it expects the company's experimental oral antiviral treatment for COVID-19 could get emergency authorization by the end of the year. "We expect to be able to see clinical data here in the back half of the year and still have the potential for an interim analysis and potential for emergency use authorization before year end," Merck CEO Robert Davis told investors at the Morgan Stanley Global Healthcare Conference on Monday. Merck and Ridgeback Biotherapeutics Inc. have been testing the investigational therapy, molnupiravir, in a Phase 3 clinical trial. There are few authorized or approved new COVID-19 treatments beyond the monoclonal antibodies developed by Eli Lilly & Co. $(LLY)$, GlaxoSmithKline (GSK.LN) and Vir Biotechnology Inc. $(VIR)$, and Regeneron Pharmaceuticals Inc. (REGN) and Gilead Sciences Inc.'s $(GILD)$ Veklury. The medical community has called for easy-to-take medications that can treat the disease caused by SARS-CoV-2. The U.S. has already purchased 1.7 million courses of molnupiravir, dependent on authorization from regulators. Merck's stock is down 7.0% for the year, while the broader S&P 500 is up 18.9%.

-Jaimy Lee

$(END)$ Dow Jones Newswires

September 14, 2021 08:38 ET (12:38 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

EPK
2021-09-22
EPK
Is this drug effective? I thought results was mixed?
- EPK:
  ?
- EPK:
  ?
- EPK:
  ?
- EPKReplyEPK:
  ?
- EPKReplyEPK:
  ?

Leave a comment

1

4

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2167314556?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-14 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2167314556","market":"us","top_or_hot":-1,"title":"Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end\n</p>\n<p>\n  Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> said it expects the company's experimental oral antiviral treatment for COVID-19 could get emergency authorization by the end of the year. \"We expect to be able to see clinical data here in the back half of the year and still have the potential for an interim analysis and potential for emergency use authorization before year end,\" Merck CEO Robert Davis told investors at the <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> Global Healthcare Conference on Monday. Merck and Ridgeback Biotherapeutics Inc. have been testing the investigational therapy, molnupiravir, in a Phase 3 clinical trial. There are few authorized or approved new COVID-19 treatments beyond the monoclonal antibodies developed by Eli Lilly &amp; Co. <a href=\"https://laohu8.com/S/LLY\">$(LLY)$</a>, GlaxoSmithKline (GSK.LN) and Vir Biotechnology Inc. <a href=\"https://laohu8.com/S/VIR\">$(VIR)$</a>, and <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc. (REGN) and Gilead Sciences Inc.'s <a href=\"https://laohu8.com/S/GILD\">$(GILD)$</a> Veklury. The medical community has called for easy-to-take medications that can treat the disease caused by SARS-CoV-2. The U.S. has already purchased 1.7 million courses of molnupiravir, dependent on authorization from regulators. Merck's stock is down 7.0% for the year, while the broader S&amp;P 500  is up 18.9%. \n</p>\n<p>\n  -Jaimy Lee \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  September 14, 2021 08:38 ET (12:38 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-14 20:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end\n</p>\n<p>\n  Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> said it expects the company's experimental oral antiviral treatment for COVID-19 could get emergency authorization by the end of the year. \"We expect to be able to see clinical data here in the back half of the year and still have the potential for an interim analysis and potential for emergency use authorization before year end,\" Merck CEO Robert Davis told investors at the <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> Global Healthcare Conference on Monday. Merck and Ridgeback Biotherapeutics Inc. have been testing the investigational therapy, molnupiravir, in a Phase 3 clinical trial. There are few authorized or approved new COVID-19 treatments beyond the monoclonal antibodies developed by Eli Lilly &amp; Co. <a href=\"https://laohu8.com/S/LLY\">$(LLY)$</a>, GlaxoSmithKline (GSK.LN) and Vir Biotechnology Inc. <a href=\"https://laohu8.com/S/VIR\">$(VIR)$</a>, and <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc. (REGN) and Gilead Sciences Inc.'s <a href=\"https://laohu8.com/S/GILD\">$(GILD)$</a> Veklury. The medical community has called for easy-to-take medications that can treat the disease caused by SARS-CoV-2. The U.S. has already purchased 1.7 million courses of molnupiravir, dependent on authorization from regulators. Merck's stock is down 7.0% for the year, while the broader S&amp;P 500  is up 18.9%. \n</p>\n<p>\n  -Jaimy Lee \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  September 14, 2021 08:38 ET (12:38 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2167314556","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2167314556","pubTimestamp":1631623080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"MW Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end\n","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来","GSK":"葛兰素史克","MRK":"默沙东","REGN":"再生元制药公司","GILD":"吉利德科学","VIR":"Vir Biotechnology, Inc."},"translate_title":"默沙东首席执行官：其实验性抗病毒新冠肺炎治疗可能在年底前获得授权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9,"VIR":0.9,"REGN":0.9,"LLY":0.9,"MRK":1,"GSK":0.9},"content_text":"MW Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end\n\n\n  Merck & Co. Inc. $(MRK)$ said it expects the company's experimental oral antiviral treatment for COVID-19 could get emergency authorization by the end of the year. \"We expect to be able to see clinical data here in the back half of the year and still have the potential for an interim analysis and potential for emergency use authorization before year end,\" Merck CEO Robert Davis told investors at the Morgan Stanley Global Healthcare Conference on Monday. Merck and Ridgeback Biotherapeutics Inc. have been testing the investigational therapy, molnupiravir, in a Phase 3 clinical trial. There are few authorized or approved new COVID-19 treatments beyond the monoclonal antibodies developed by Eli Lilly & Co. $(LLY)$, GlaxoSmithKline (GSK.LN) and Vir Biotechnology Inc. $(VIR)$, and Regeneron Pharmaceuticals Inc. (REGN) and Gilead Sciences Inc.'s $(GILD)$ Veklury. The medical community has called for easy-to-take medications that can treat the disease caused by SARS-CoV-2. The U.S. has already purchased 1.7 million courses of molnupiravir, dependent on authorization from regulators. Merck's stock is down 7.0% for the year, while the broader S&P 500  is up 18.9%. \n\n\n  -Jaimy Lee \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  September 14, 2021 08:38 ET (12:38 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[{"id":869655065,"gmtCreate":1632284410857,"gmtModify":1676530743126,"author":{"id":"3582064943200061","authorId":"3582064943200061","name":"EPK","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3582064943200061","authorIdStr":"3582064943200061"},"htmlText":"Is this drug effective? &nbsp;I thought results was mixed?","listText":"Is this drug effective? &nbsp;I thought results was mixed?","text":"Is this drug effective? I thought results was mixed?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":28,"repostSize":0,"link":"https://ttm.financial/post/869655065","repostId":2167314556,"repostType":2,"repost":{"id":"2167314556","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631623080,"share":"https://ttm.financial/m/news/2167314556?lang=en_US&edition=fundamental","pubTime":"2021-09-14 20:38","market":"us","language":"en","title":"Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end","url":"https://stock-news.laohu8.com/highlight/detail?id=2167314556","media":"Dow Jones","summary":"MW Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end\n","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end\n</p>\n<p>\n  Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> said it expects the company's experimental oral antiviral treatment for COVID-19 could get emergency authorization by the end of the year. \"We expect to be able to see clinical data here in the back half of the year and still have the potential for an interim analysis and potential for emergency use authorization before year end,\" Merck CEO Robert Davis told investors at the <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> Global Healthcare Conference on Monday. Merck and Ridgeback Biotherapeutics Inc. have been testing the investigational therapy, molnupiravir, in a Phase 3 clinical trial. There are few authorized or approved new COVID-19 treatments beyond the monoclonal antibodies developed by Eli Lilly &amp; Co. <a href=\"https://laohu8.com/S/LLY\">$(LLY)$</a>, GlaxoSmithKline (GSK.LN) and Vir Biotechnology Inc. <a href=\"https://laohu8.com/S/VIR\">$(VIR)$</a>, and <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc. (REGN) and Gilead Sciences Inc.'s <a href=\"https://laohu8.com/S/GILD\">$(GILD)$</a> Veklury. The medical community has called for easy-to-take medications that can treat the disease caused by SARS-CoV-2. The U.S. has already purchased 1.7 million courses of molnupiravir, dependent on authorization from regulators. Merck's stock is down 7.0% for the year, while the broader S&amp;P 500  is up 18.9%. \n</p>\n<p>\n  -Jaimy Lee \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  September 14, 2021 08:38 ET (12:38 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-14 20:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end\n</p>\n<p>\n  Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> said it expects the company's experimental oral antiviral treatment for COVID-19 could get emergency authorization by the end of the year. \"We expect to be able to see clinical data here in the back half of the year and still have the potential for an interim analysis and potential for emergency use authorization before year end,\" Merck CEO Robert Davis told investors at the <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> Global Healthcare Conference on Monday. Merck and Ridgeback Biotherapeutics Inc. have been testing the investigational therapy, molnupiravir, in a Phase 3 clinical trial. There are few authorized or approved new COVID-19 treatments beyond the monoclonal antibodies developed by Eli Lilly &amp; Co. <a href=\"https://laohu8.com/S/LLY\">$(LLY)$</a>, GlaxoSmithKline (GSK.LN) and Vir Biotechnology Inc. <a href=\"https://laohu8.com/S/VIR\">$(VIR)$</a>, and <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc. (REGN) and Gilead Sciences Inc.'s <a href=\"https://laohu8.com/S/GILD\">$(GILD)$</a> Veklury. The medical community has called for easy-to-take medications that can treat the disease caused by SARS-CoV-2. The U.S. has already purchased 1.7 million courses of molnupiravir, dependent on authorization from regulators. Merck's stock is down 7.0% for the year, while the broader S&amp;P 500  is up 18.9%. \n</p>\n<p>\n  -Jaimy Lee \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  September 14, 2021 08:38 ET (12:38 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","GSK":"葛兰素史克","MRK":"默沙东","REGN":"再生元制药公司","GILD":"吉利德科学","VIR":"Vir Biotechnology, Inc."},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167314556","content_text":"MW Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end\n\n\n  Merck & Co. Inc. $(MRK)$ said it expects the company's experimental oral antiviral treatment for COVID-19 could get emergency authorization by the end of the year. \"We expect to be able to see clinical data here in the back half of the year and still have the potential for an interim analysis and potential for emergency use authorization before year end,\" Merck CEO Robert Davis told investors at the Morgan Stanley Global Healthcare Conference on Monday. Merck and Ridgeback Biotherapeutics Inc. have been testing the investigational therapy, molnupiravir, in a Phase 3 clinical trial. There are few authorized or approved new COVID-19 treatments beyond the monoclonal antibodies developed by Eli Lilly & Co. $(LLY)$, GlaxoSmithKline (GSK.LN) and Vir Biotechnology Inc. $(VIR)$, and Regeneron Pharmaceuticals Inc. (REGN) and Gilead Sciences Inc.'s $(GILD)$ Veklury. The medical community has called for easy-to-take medications that can treat the disease caused by SARS-CoV-2. The U.S. has already purchased 1.7 million courses of molnupiravir, dependent on authorization from regulators. Merck's stock is down 7.0% for the year, while the broader S&P 500  is up 18.9%. \n\n\n  -Jaimy Lee \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  September 14, 2021 08:38 ET (12:38 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1,"symbols_score_info":{"GILD":0.9,"VIR":0.9,"REGN":0.9,"LLY":0.9,"MRK":1,"GSK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":103972836,"gmtCreate":1663416674175,"gmtModify":1663416677912,"authorId":3582064943200061,"author":{"id":3582064943200061,"idStr":"3582064943200061","authorId":3582064943200061,"name":"EPK","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":869655065,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">?</span>","text":"<span class=\"s1\">?</span>","html":"<span class=\"s1\">?</span>"},{"id":103945006,"gmtCreate":1663283886374,"gmtModify":1663283890643,"authorId":3582064943200061,"author":{"id":3582064943200061,"idStr":"3582064943200061","authorId":3582064943200061,"name":"EPK","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":869655065,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">?</span>","text":"<span class=\"s1\">?</span>","html":"<span class=\"s1\">?</span>"},{"id":103789632,"gmtCreate":1662433519340,"gmtModify":1663258294632,"authorId":3582064943200061,"author":{"id":3582064943200061,"idStr":"3582064943200061","authorId":3582064943200061,"name":"EPK","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":869655065,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">?</span>","text":"<span class=\"s1\">?</span>","html":"<span class=\"s1\">?</span>"},{"id":103702821,"gmtCreate":1661949361136,"gmtModify":1663257849436,"authorId":3582064943200061,"author":{"id":3582064943200061,"idStr":"3582064943200061","authorId":3582064943200061,"name":"EPK","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3582064943200061,"repliedAuthor":{"id":3582064943200061,"idStr":"3582064943200061","authorId":3582064943200061,"name":"EPK","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":869655065,"type":1,"supId":103119049,"prevId":103579971,"content":"<span class=\"s1\">?</span>","text":"<span class=\"s1\">?</span>","html":"<span class=\"s1\">?</span>"},{"id":103664905,"gmtCreate":1661759607756,"gmtModify":1663257578847,"authorId":3582064943200061,"author":{"id":3582064943200061,"idStr":"3582064943200061","authorId":3582064943200061,"name":"EPK","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3582064943200061,"repliedAuthor":{"id":3582064943200061,"idStr":"3582064943200061","authorId":3582064943200061,"name":"EPK","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":869655065,"type":1,"supId":103119049,"prevId":103561581,"content":"<span class=\"s1\">?</span>","text":"<span class=\"s1\">?</span>","html":"<span class=\"s1\">?</span>"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2167314556","isCrawlerRequest":true}